ArticleTargeted oncology2020

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Julie G Fisher et al.PubMed ↗Publisher ↗

No numbers read from the abstract.